Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878716 | 0.83 | CRHR1 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21950833 | 0.82 | CRHR1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9345742 | 0.81 | CA1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30250475 | 0.75 | CA1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1134723 | 0.75 | CA1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19297784 | 0.73 | APP (0.49) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL276828 | 0.72 | EGFR (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29785358 | 0.72 | EGFR (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3595820 | 0.72 | HPGD (0.36) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6449465 | 0.72 | CA1 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | META PLATFORMS TECHNOLOGIES, LLC | 2024-05-09 | — | — | US | disclosed |
| EP-3245212-B1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-10053471-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-21 | — | — | US | disclosed |
| EP-3083567-B1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20180002349-A1 | New Azabenzimidazole Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GBMH (DE) | 2018-01-04 | — | — | US | disclosed |
| EP-3044211-B1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-01-03 | — | — | EP | disclosed |
| EP-3245212-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-9802901-B2 | Antibacterial 2H-indazole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-31 | — | — | US | disclosed |
| US-9624206-B2 | Antibacterial 1H-indazole and 1H-indole derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20170029411-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-02 | — | — | US | disclosed |
| EP-3083567-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20160221959-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-04 | — | — | US | disclosed |
| WO-2016113299-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | disclosed |
| EP-3044211-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015091741-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015036964-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-19 | — | — | WO | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221959-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | H1-3, MRPL21, H1-0 | CA12 4328/4885CA1 4368/4885CA2 3022/4885 |
| US-20180002349-A1 | New Azabenzimidazole Derivatives | PRKAB2, PRKAB1, PRKAR2B | CA12 4593/4885CA1 4690/4885CA2 1827/4885 |
| US-20170029411-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | MRPL21, PYM1, DRD3 | CA12 4759/4885CA1 4264/4885CA2 3530/4885 |
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | AR, OR10J3, ESRRG | CA12 1442/4885CA1 2106/4885CA2 1583/4885 |
| US-10053471-B2 | Azabenzimidazole derivatives | PRKAB2, PRKAB1, PRKAG2 | CA12 4505/4885CA1 4651/4885CA2 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.